23 completed, 12 terminated, 11 recruiting, 10 active not recruiting. 59 Phase 1, 25 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 59 | Completed 23, Terminated 12, Recruiting 11, Active not recruiting 10, Suspended 3 |
| Phase 2 | 25 | Completed 10, Active not recruiting 7, Terminated 6, Recruiting 1, Suspended 1 |
Follow Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Clear Cell Renal Cell Carcinoma trials Research Report on Clear Cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01) Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 15 | 2026-08-23 | 2026-10-14 |
| A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide) - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | PeptiDream Inc. | 60 | 2026-07-07 | 2026-09-18 |
| Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma Cyclophosphamide, Fludarabine, LNK001 - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-02 | 2026-10-09 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-12 | 2026-08-11 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NEO-811 - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Neomorph, Inc | 30 | 2025-12-19 | 2026-10-05 |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| A Phase 1 Trial of ADI-270 in ccRCC ADI-270, Fludarabine, Cyclophosphamide - Clear Cell Renal Cell Carcinoma | Phase 1 | Terminated | Adicet Therapeutics | 10 | 2024-12-12 | 2026-10-27 |
| 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC 68Ga-NYM096 PET/CT and 177Lu-NYM096 - Clear Cell Renal Cell Carcinoma | Phase 1 | Suspended | Peking Union Medical College Hospital | 20 | 2024-11-21 | 2025-12-31 |
| A Study of MGC026 in Participants With Advanced Solid Tumors MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | MacroGenics | 394 | 2024-03-06 | 2026-10-28 |
| Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies BDC-3042, Cemiplimab - Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma | Phase 1 | Terminated | Bolt Biotherapeutics, Inc. | 17 | 2023-10-11 | 2025-11-17 |
| Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 1 | Suspended | City of Hope Medical Center | 31 | 2023-10-06 | 2026-10-08 |
| Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC 177Lu girentuximab, Nivolumab, Cabozantinib - Advanced Cancer, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Suspended | M.D. Anderson Cancer Center | 100 | 2023-06-30 | 2026-10-08 |
| Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma 89Zr-Girentuximab - Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma | Phase 1 | Completed | Telix Pharmaceuticals (Innovations) Pty Limited | 10 | 2023-06-26 | 2023-12-11 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors CTX131 - Clear Cell Renal Cell Carcinoma, Cervical Carcinoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics AG | 19 | 2023-03-13 | 2025-11-26 |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors casdatifan, Cabozantinib, Zimberelimab - Clear Cell Renal Cell Carcinoma, Solid Tumors | Phase 1 | Recruiting | Arcus Biosciences, Inc. | 362 | 2022-10-26 | 2026-10-05 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
| Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab Selenomethionine (SLM), Axitinib, Pembrolizumab - Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | Phase 1 / Phase 2 | Active not recruiting | Mohammed Milhem | 55 | 2022-09-19 | 2025-12-10 |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma XmAb819 - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Xencor, Inc. | 307 | 2022-06-13 | 2026-08-03 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) HC-7366 - Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer | Phase 1 | Terminated | HiberCell, Inc. | 35 | 2022-02-23 | 2024-03-08 |
Showing 20 of 59. Sign in to see all of them.
Carcinoma, Renal Cell (59) · Kidney Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (6) · Neoplasm Metastasis (6) · Colorectal Neoplasms (5) · Melanoma (5) · Squamous Cell Carcinoma of Head and Neck (5) · Neoplasms (4) · Ovarian Neoplasms (4) · Small Cell Lung Carcinoma (4) · Triple Negative Breast Neoplasms (4) · Urinary Bladder Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Ovarian Epithelial (3) · Clear-cell metastatic renal cell carcinoma (3)
Adenocarcinoma (59) · Female Urogenital Diseases (59) · Female Urogenital Diseases and Pregnancy Complications (59) · Male Urogenital Diseases (59) · Neoplasms by Histologic Type (59) · Neoplasms by Site (59) · Neoplasms, Glandular and Epithelial (59) · Urogenital Diseases (59) · Urologic Diseases (59) · Kidney Diseases (58) · Urogenital Neoplasms (58) · Urologic Neoplasms (58) · Carcinoma (57) · Neoplasms (55) · Kidney Neoplasms (44)
Nivolumab (12) · Bevacizumab (6) · Magnetic Resonance Spectroscopy (6) · cabozantinib (6) · Ipilimumab (5) · pembrolizumab (5) · Cyclophosphamide (4) · Axitinib (3) · CTLA-4 Antigen (3) · Sunitinib (3) · belzutifan (3) · fludarabine (3) · fludarabine phosphate (3) · Biopsy (2) · Cyclosporine (2)
National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Fred Hutchinson Cancer Center (2) · MacroGenics (2) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Roswell Park Cancer Institute (2) · Telix Pharmaceuticals (Innovations) Pty Limited (2) · X4 Pharmaceuticals (2) · 23andMe, Inc. (1) · Adicet Therapeutics (1) · Ajjai Alva, MD (1) · Amgen (1) · Aravive, Inc. (1)
United States (52) · Australia (6) · Spain (5) · Canada (4) · China (4) · Germany (4) · South Korea (4) · France (3) · United Kingdom (3) · Belgium (2) · Italy (2) · Japan (2) · Ireland (1) · Netherlands (1) · Portugal (1)
Brenda Sandmaier (2) · Glenn Liu (2) · Saby George (2) · Sumanta K Pal (2) · Ajjai Alva, M.D. (1) · Alexandra Drakaki, MD (1) · Andrea B Apolo (1) · Arash Yavari, MBBS (1) · Brian Rini (1) · Chaitanya R Divgi, MD (1) · Elizabeth Henry (1)
PMID 32499241, PMID 17395103, PMID 18272024, PMID 22259028, PMID 24474568, PMID 29257710, PMID 31654285, PMID 32915679, PMID 32925563, PMID 33305087, PMID 33507454, PMID 33888901, PMID 35031545, PMID 35228755, PMID 35507017, PMID 36464584, PMID 36536472, PMID 38008031, PMID 38302476, PMID 38954785, PMID 39651931, PMID 40549043, PMID 40592738, PMID 40712111, PMID 41444455
U01CA062491 (3), U01CA070095 (3), P01CA018029 (2), P30CA014520 (2), P30CA015704 (2), P30CA033572 (2), UM1CA186712 (2), UM1CA186717 (2), 2023 (1), 2025 (1), N01CM62205 (1), P30CA006973 (1), P30CA008748 (1), P30CA016056 (1), P30CA068485 (1)